Intensity Therapeutics, Inc. (“Intensity”), a clinical-stage biotechnology company developing proprietary intratumoral products to kill tumors and increase recognition of cancers by the immune system, today announced two poster presentations at the occasion of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually June 4-8.
Title: A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable, metastatic solid tumors refractory to treatment
Authors: El-Khoueiry, AB, et al.
Session: Developmental Therapeutics – Immunotherapy
Type of session: Poster session
Title: Early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas
Authors: Ingham, M. et al.
Type of session: Poster session
“INT230-6 is a novel, proprietary, locally delivered anticancer product candidate that has shown very promising clinical results as monotherapy in a basket study of patients with advanced and refractory disease,” said Lewis H. Bender, President and CEO of Intensity Therapeutics. “We are delighted that ASCO has given us the opportunity to share our encouraging results in two presentations. The data that will be reported in our first poster will update our safety and efficacy results for patients receiving INT230-6 alone or in combination with pembrolizumab. the second presentation details the preliminary results of INT230-6 with or without ipilimumab to treat sarcomas, a complex type of cancer with high unmet medical needs. “
INT230-6, Intensity’s proprietary research lead product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity’s proprietary DfuseRx℠ technology platform. The drug is made up of two strong and proven anticancer agents, cisplatin and vinblastine, and a penetration enhancing molecule that helps disperse drugs through tumors for diffusion into cancer cells.
About Intensity Therapeutics Clinical Studies
INT230-6 is currently being evaluated in several phase 2 cohorts (NCT03058289) in patients with various advanced solid tumors in Study IT-01. In 2019, the Company signed a clinical collaboration agreement with Merck Sharpe & Dohme (Merck) to evaluate the combination of INT230-6, the flagship product candidate of Intensity, and KEYTRUDA® (pembrolizumab), the anti- Merck PD-1 (programmed death receptor) 1) treatment, in patients with advanced malignancies of the pancreas, colon, squamous cells and bile ducts. In 2020, the Company entered into a clinical collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination INT230-6, with the Bristol Myers Squibb anti-CTLA-4 antibody, Yervoy® (ipilimumab), in patients with advanced liver, breast and sarcoma cancers. In 2021, the company entered into agreements with the Ottawa Hospital Research Institute and the Ontario Cancer Research Institute to study INT230-6 in a randomized, controlled, phase 2 neoadjuvant study in women. with early-stage breast cancer (INVINCIBLE study) (NCT04781725).
About Intensity Therapeutics
Intensity Therapeutics, Inc. is a privately-held, clinical-stage biotechnology company that has pioneered a novel immune approach to treat solid tumor cancers. Intensity is leveraging its DfuseRx to technology platform to create new formulations of proprietary drugs that, after direct injection, rapidly disperse into a tumor and deliver therapeutic agents into cancer cells. Intensity’s product candidates have the potential to induce an adaptive immune response that attacks not only the injected tumor, but also uninjected tumors. The Company signed a Research and Development Cooperation Agreement (CRADA) with the vaccines arm of the National Cancer Institute (NCI) in 2014 and has partnerships with Merck and Bristol Myers Squibb. For more information, please visit www.intensitytherapeutics.com and follow us on Twitter @Intensity.
This press release contains forward-looking statements regarding the plans, future operations and objectives of Intensity Therapeutics. Such statements involve risks, uncertainties and other known and unknown factors which may cause actual performance or achievements to differ materially from those currently expected. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.
YERVOY® is a registered trademark of Bristol Myers Squibb.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20210520005106/en/
Burns McClellan for Intensity Therapy
T: 212.213.0006 | M: 646.382.3403
T: 212.213.0006 x315